Desloratadine

證據等級: L5

預測適應症: 6 個

Desloratadine: From Allergic Rhinitis/Chronic Urticaria to Cold Urticaria

One-Sentence Summary

Desloratadine is a second-generation H1-antihistamine commonly used for allergic rhinitis and chronic urticaria. The TxGNN model predicts it may be effective for Cold Urticaria (Acquired Cold Urticaria, ACU), with 3 clinical trials and 7 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Allergic rhinitis / chronic urticaria (general second-generation antihistamine use; not documented in the Finland regulatory dataset provided)
Predicted New Indication	Cold Urticaria
TxGNN Prediction Score	99.94%
Evidence Level	L1
Finland Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed official mechanism-of-action data was not retrievable from DrugBank in this evidence pack. Based on known pharmacology, desloratadine is a selective, peripherally-acting second-generation H1-receptor antagonist — the active metabolite of loratadine.

Cold urticaria is triggered by cold-induced degranulation of cutaneous mast cells, with histamine release driving the wheal-and-flare response. Because desloratadine directly blocks the H1 receptor downstream of this histamine release, its established antihistamine activity maps mechanistically onto cold urticaria's pathophysiology, rather than requiring a novel mode of action.

This is reflected in the repurposing rationale supplied with the prediction: H1-antihistamines are already recommended by EAACI/GA²LEN urticaria guidelines as first-line therapy for cold urticaria, and dose-escalation (updosing) strategies with desloratadine specifically have been studied. This gives the TxGNN prediction direct, guideline-consistent mechanistic support rather than a purely inferential link.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01444196	Phase 4	Completed	30	Multi-center, double-blind, dose-escalating study assessing the desloratadine dose (5/10/20 mg) sufficient to inhibit cold urticaria symptoms.
NCT00600847	Phase 4	Completed	33	Randomized, double-blind, placebo-controlled crossover study comparing 5 mg vs. 20 mg desloratadine on experimentally induced cold urticaria lesions (thermography/volumetry); hypothesizes updosing (20 mg) is more effective than standard dose.
NCT01940393	Phase 4	Completed	150	Evaluation of the inhibitory effect of 5 antihistamines (including desloratadine) in urticaria; class-comparison evidence rather than desloratadine-specific.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
14754651	2004	RCT	J Dermatolog Treat	5 mg desloratadine for 4 days tested with ice-cube provocation in 12 cold urticaria patients before/after treatment.
19201016	2009	RCT	J Allergy Clin Immunol	High-dose desloratadine decreases wheal volume and improves cold provocation thresholds vs. standard dose in ACU patients (randomized, placebo-controlled, crossover).
22242678	2012	RCT	Br J Dermatol	Randomized controlled trial of H1-antihistamine dose escalation using critical temperature threshold measurement for cold urticaria.
15516152	2004	Review	Drugs	Review of chronic urticaria aetiology, management, and current/future treatment options (including antihistamine class).
19032340	2008	Review	Allergy	Review of ebastine (a different antihistamine) in allergic rhinitis and chronic idiopathic urticaria; class-level, not desloratadine-specific.
29698807	2018	Review/Case series	J Allergy Clin Immunol Pract	Describes food-dependent cold urticaria as a new variant of physical urticaria.
38025339	2023	Case report	Qatar Med J	First reported case of cold-induced urticaria following black ant bite-induced anaphylaxis.

Finland Market Information

Desloratadine is currently not marketed in Finland per the available regulatory data, and no marketing authorizations were found (0 licenses on record).

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Cold urticaria is supported by an L1 evidence level, including two completed Phase 4 RCTs specifically dosing desloratadine in ACU patients and three additional published RCTs (Juhlin 2004, Siebenhaar 2009, Magerl 2012) with a mechanism consistent with EAACI/GA²LEN guideline-recommended therapy. However, desloratadine is not currently marketed in Finland and TFDA-equivalent labeling/safety data (warnings, contraindications, DDI) were not retrievable, so guardrails on safety and regulatory pathway are required before advancing.

To proceed, the following is needed:

Official package insert / label warnings and contraindications (currently a Blocking data gap)
Confirmed drug-drug interaction profile
Formal mechanism-of-action documentation from DrugBank
Regulatory pathway assessment for introducing/relabeling desloratadine for cold urticaria in a market where it is not currently authorized
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.